| Name | Title | Contact Details |
|---|
SIGA Technologies is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Curemark, LLC is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of neurological disorders. Curemark`s pipeline includes preclinical and clinical-stage programs for the treatment of Autism, ADHD, addiction, Schizophrenia and Parkinson`s disease.
Lycera is a biopharmaceutical company that seeks to uncover new small molecule therapies for the treatment of autoimmune diseases and cancer. Our approach builds on an in-depth understanding of the orchestration of immune response in disease progression. When working correctly, the immune system can respond aggressively and with precise targeting to eliminate infectious pathogens or cancer cells. Incorrect regulation can cause the immune system to attack healthy tissue as foreign, supporting onset and progression of autoimmune disease while disruption of anti-tumor immune responses can shield cancer cells from the immune system and allow them to proliferate. Lycera is rapidly building a portfolio of selective immune modulators with mechanisms we believe will translate into improved outcomes for patients. With senior leadership and a team of scientists who represent the best of their fields, Lycera has the expertise and insight necessary to develop innovative therapies able to restore immune balance and significantly improve treatment for patients affected by these diseases around the world. Lycera product development programs are enhanced by our established global relationships with many leading chemists, scientists and clinical researchers. We are currently advancing novel small molecule compounds from distinct, yet complementary, areas of research, including immune metabolism, cell signaling and immune cell differentiation.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry seven years in a row by the Dow Jones Sustainability Indices. The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
Adagio Therapeutics, Inc` is a clinical-stage a biotechnology company developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1 and additional pre-emergent coronaviruses` Our candidates are optimized using Adimab’s industry-leading antibody engineering capabilities and are designed to provide patients and clinicians with an unsurpassed combination of potency, breadth, durable protection (via half-life extension), manufacturability, tolerability, and affordability` Our portfolio of SARS-CoV-2 antibodies includes multiple, non-competing antibodies with distinct binding epitopes` Pre-clinical data show that our lead antibody ADG20 matches or exceeds the potency and coverage of other clinical SARS-CoV-2 antibody programs` We plan to advance ADG20 aggressively through global clinical trials for both the prevention and treatment of symptomatic COVID-19 and anticipate data from both prevention and treatment clinical trials in 2021` Adagio has secured manufacturing capacity for the production of ADG20 with third party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch`